Table 2.
Correlation of SLC2A1 expression with clinicopathological features in patients
| Clinicopathological Features | SLC2A1 negative (%) | SLC2A1 positive (%) | p |
|---|---|---|---|
| Age (years) | 0.447 | ||
| ≤ 55 | 32 (61.5) | 20 (38.5) | |
| > 55 | 25 (62.5) | 15 (37.5) | |
| Unknow | 0 (0) | 1 (100) | |
| Gender | 0.929 | ||
| Male | 51 (61.4) | 32 (38.6) | |
| Female | 6 (60) | 4 (40) | |
| T stage | 0.139 | ||
| T1–2 | 31 (72.1) | 12 (27.9) | |
| T3–4 | 22 (52.4) | 20 (47.6) | |
| Unknow | 4 (50) | 4 (50) | |
| N stage | 0.685 | ||
| N0 | 51 (61.4) | 32 (38.6) | |
| N1 | 1 (100) | 0 (0) | |
| Unknow | 5 (55.6) | 4 (44.4) | |
| M stage | 0.345 | ||
| M0 | 53 (63.1) | 31 (36.9) | |
| M1 | 0 (0) | 1 (100) | |
| Unknow | 4 (50) | 4 (50) | |
| Stage | 0.139 | ||
| Stage I–II | 31 (72.1) | 12 (27.9) | |
| Stage III–IV | 22 (52.4) | 20 (47.6) | |
| Unknow | 4 (50) | 4 (50) | |
| Grade | 0.003 | ||
| G1–2 | 44 (72.1) | 17 (27.9) | |
| G3 | 13 (40.6) | 19 (59.4) | |